The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2026 | Biomarker correlates of clinical outcomes from the Phase Ib study of JNJ-4496 in patients with DLBCL
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, provides insight into the biomarker correlates of clinical outcomes from the Phase Ib study (NCT05421663) of JNJ-90014496 (JNJ-4496; prizloncabtagene autoleucel) in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Patel notes that this dual-targeting approach may help overcome antigen escape, a potential limitation of single-antigen-targeting CAR T-cells, and that future head-to-head clinical trials will help define the role of dual-antigen-targeting CAR-T constructs in the DLBCL treatment landscape. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a dual antigen-targeting CAR T-cell, targeting CD19 and CD20, that was studied in patients with relapsed/refractory DLBCL. We presented clinical data last summer. Here we’re presenting some of the translational correlates from the trial, and I think at the high level, what we see from this CAR T-cell is robust expansion of the CAR T-cell across a variety of different dose ranges, so from weight-based dosing to two flat doses...
So this is a dual antigen-targeting CAR T-cell, targeting CD19 and CD20, that was studied in patients with relapsed/refractory DLBCL. We presented clinical data last summer. Here we’re presenting some of the translational correlates from the trial, and I think at the high level, what we see from this CAR T-cell is robust expansion of the CAR T-cell across a variety of different dose ranges, so from weight-based dosing to two flat doses. And importantly, we also were able to look at whether antigen expression at baseline, so how bright CD19 or 20 or both were, correlated with outcomes. And what we could see is very good clinical outcomes associated with a range of antigen expression. So even in patients that had low CD19 and low CD20, achieving complete responses. So I think one of the things that is very exciting about dual-antigen targeting CAR T cells is they may offer us a way to hopefully overcome the potential for antigen escape. So very exciting data to see from early experience.
We recognize from our experience with CD19 alone targeting CAR T-cells that somewhere around a quarter to a third of patients who progress after those therapies have low CD19 or absent CD19 expression. So by introducing an additional antigen target, CD20, we’re hoping to improve the durable response rate. And so this 19/20 CAR T cell, like others, is now starting to move towards head-to-head clinical trials that will help us define if a dual antigen targeting approach is superior to a single antigen targeting approach. So hopefully it will help us to define exactly where a 19/20 CAR T-cell belongs.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
